Patents Examined by Lynette R. F. Smith
  • Patent number: 6955908
    Abstract: The invention features a biologically pure culture of a newly identified single-celled organism Spiky Rotating Cells (SPR), methods to diagnose an SPR infection in a human patient, an instrument for collecting and detecting an SPR infection, and methods for treating an SPR infection.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: October 18, 2005
    Inventor: Barbara B. Lambl
  • Patent number: 6955924
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: October 18, 2005
    Assignee: BioStratum, Inc.
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Patent number: 6951756
    Abstract: The invention relates to a method for preparing closed bacterial ghosts by means of vesicle membrane fusion and to the bacterial ghosts which can be obtained in this way. Active compounds, e.g. genetic material, cell components, pharmaceutical and agricultural active compounds and also markers or dyes can be packaged in the closed bacterial ghosts. Metabolic functions and, where appropriate, the ability of the cells to proliferate can be restored on packaging genetic material in the bacterial ghosts. The closed ghosts can be used in medicine, in the agricultural sphere and in biotechnology.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: October 4, 2005
    Inventors: Werner Lubitz, Susanne Paukner
  • Patent number: 6942858
    Abstract: Purified, host-specific, non-toxic, wide host range and virulent bacteriophage preparations that are effective in killing bacterial organisms in vivo are disclosed. Also disclosed are compositions containing these bacteriophages, methods of making the bacteriophage preparations and methods of treating bacterial infections using the compositions. Methods of treating bacterial infections using the compositions containing the bacteriophages in combination with conventional antibiotics also are disclosed.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: September 13, 2005
    Assignee: Nymox Corporation
    Inventors: Hossein A. Ghanbari, Paul Averback
  • Patent number: 6942986
    Abstract: The production of a purified extracellular bacterial signal called autoinducer-2 is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. Autoinducer-2 stimulates LuxQ luminescence genes, and is believed also to stimulate a variety of pathogenesis related genes in the bacterial species that produce it. A new class of bacterial genes is involved in the biosynthesis of autoinducer-2.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: September 13, 2005
    Assignees: Princeton University, University Technologies International
    Inventors: Bonnie L. Bassler, Michael G. Surette
  • Patent number: 6939703
    Abstract: The present invention relates to novel amylolytic enzymes having improved characteristics for the use in starch degradation, in textile or paper desizing and in household detergent compositions. The disclosed ?-amylases show surprisingly improved properties with respect to the activity level and the combination of thermostability and a higher activity level. These improved properties make them more suitable for the use under more acidic or more alkaline conditions. The improved properties allow also the reduction of the Calcium concentration under application conditions without a loss of performance of the enzyme.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: September 6, 2005
    Assignee: Genencor International, Inc.
    Inventors: Jan M. Van Der Laan, Wolfgang Aehle
  • Patent number: 6936259
    Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: August 30, 2005
    Assignee: University of Saskatchewan
    Inventors: Andrew A. Potter, Jose Perez-Casal, Michael Fontaine, Xinming Song
  • Patent number: 6936435
    Abstract: The production of a purified extracellular bacterial signal called autoinducer-2 is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. Autoinducer-2 stimulates LuxQ luminescence genes, and is believed also to stimulate a variety of pathogenesis related genes in the bacterial species that produce it. A new class of bacterial genes is involved in the biosynthesis of autoinducer-2.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: August 30, 2005
    Assignees: Princeton University, University Technologies Internat.
    Inventors: Bonnie L. Bassler, Michael G. Surette
  • Patent number: 6923973
    Abstract: Disclosed are peptide and DNA compositions surprisingly found to be effective in generating immune responses against the pathogenic fungi Coccidioides spp., the causative agents of coccidioidomycosis and Valley Fever. The invention thus provides peptides and DNA constructs, combinations and related biological compositions, and prophylactic and therapeutic methods of using such components to generate effective immune responses against Coccidioides spp., including C. immitis.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: August 2, 2005
    Assignee: Board of Regents, The University of Texas System
    Inventors: Rebecca A. Cox, D. Mitchell Magee, Chengyong Jiang
  • Patent number: 6921538
    Abstract: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: July 26, 2005
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Patent number: 6916478
    Abstract: The invention relates to novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, methods for preparing same, and their use in the prevention and treatment of infectious diseases.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 12, 2005
    Assignee: University of Guelph
    Inventors: Jagath L. Kadurugamuwa, Terry J. Beveridge
  • Patent number: 6916474
    Abstract: The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities for Bacillus anthracis antigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection by Bacillus anthracis.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: July 12, 2005
    Assignee: Board of Regents, The University of Texas System
    Inventors: Barrett R. Harvey, George Georgiou, Brent L. Iverson
  • Patent number: 6913767
    Abstract: Methods and compositions are provided for the encapsulation of antigens in PLGA microspheres for use as vaccines. Such microspheres can also contain adjuvants. Mixtures of microspheres are provided which release antigen at desired intervals to provide boosts with antigen.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: July 5, 2005
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Amy Lim, Michael Frank Powell
  • Patent number: 6913895
    Abstract: This invention relates to the field of bacterial transglycosylase reactions. The invention is directed to methods for assaying for transglycosylase activity, methods of identifying inhibitors of transglycosylase activity, inhibitors identified by such methods, and methods of identifying the stage of inhibition at which such inhibitors act.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: July 5, 2005
    Assignee: Advanced Medicine East, Inc.
    Inventors: Robert C. Goldman, Arthur A. Branstrom
  • Patent number: 6913756
    Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: July 5, 2005
    Assignee: The UAB Research Foundation
    Inventor: John F. Kearney
  • Patent number: 6908994
    Abstract: A collagen-binding MSCRAMM entitled Ace from enterococcal bacteria is provided which was homologous to the ligand-binding region of Cna, the collagen-binding MSCRAMM from Staphylococcus aureus, and which can be utilized in a similar manner as other collagen-binding MSCRAMMs to inhibit adhesion of enterococcal bacteria to extracellular matrix proteins. The N-terminal region of Ace contained a region (residues 174-319), or A domain, which appears to be equivalent to the minimal ligand-binding region of the collagen-binding protein Cna (Cna 151-318), and contains several 47-residue tandem repeat units, called B domain repeat units, between the collagen-binding site and cell wall-associated regions. The Ace protein of the invention can thus be utilized in methods of preventing and/or treating enterococcal infection, and in addition, antibodies raised against Ace, or its A domain, can be used to effectively inhibit the adhesion of enterococcal cells to a collagen substrate.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: June 21, 2005
    Assignees: The Texas A&M University System, Board of Regents of the University of Texas System
    Inventors: Rebecca L. Rich, Bernd Kriekemeyer, Rick T. Owens, Magnus Hook, Barbara E. Murray, Sreedhar R. Nallapareddy, George M. Weinstock
  • Patent number: 6905691
    Abstract: The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of randomly inserted, transposon mutants in which attenuation was determined as a reduction in virulence of the organism in the mouse model of infection. Site directed mutation of the gene results in a strain which shows at least 4 logs of attenuation when delivered both orally and intravenously. Animals vaccinated with such a strain are protected against subsequent challenge with the parent wild type strain. Finally, heterologous antigens such as the non-toxic and protective, binding domain from tetanus toxin, fragment C, can be delivered via the mucosal immune system using such strains of bacteria. This results in the induction of a fully protective immune response to subsequent challenge with native tetanus toxin.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: June 14, 2005
    Assignee: Celltech Pharma Europe Limited
    Inventors: Steven Neville Chatfield, Gordon Dougan, Mark Sydenham
  • Patent number: 6902903
    Abstract: Novel methods, membrane supports and immunodiagnostic test kits for diagnosing Helicobacter pylori infection, are disclosed. The methods can also be used to monitor the progress of treatment of an infection. The methods, supports and kits employ both type-common and type-specific H. pylori antigens and can conveniently be performed in a single-step assay format. The methods provide for highly accurate results and discriminate between H. pylori Type I and H. pylori Type II infection so that an accurate diagnosis can be accomplished.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: June 7, 2005
    Assignee: Chiron Corporation
    Inventors: Stella Quan, Pablo Valenzuela, Alan Polito
  • Patent number: 6900029
    Abstract: A separation procedure for separating a selected desired or undesired population from a biological sample utilizing relatively heavy, dense particles and gravity sedimentation. The particles have one or more reactants bound thereto which are specific to and will bind with the selected population. The particles preferably are mixed with the sample by repeatedly causing the particles to settle through a substantial portion of the sample to bind to the selected population. The particles with the bound selected population then are allowed to preferentially settle in the sample and the supernatant including an enriched population is separated from the particles with the selected population bound thereto. The enriched populations in the biological sample supernatant can be further enriched by multiple removal steps.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: May 31, 2005
    Assignee: Miltenyi Biotec GmbH
    Inventors: Wallace H. Coulter, Robert K. Zwerner, Robert J. Schmittling, Thomas R. Russell
  • Patent number: 6900291
    Abstract: The present invention relates to methods and materials for the detection and quantitation 8-OH-Ade in biological specimens. Specifically, the present invention is directed to a group of highly specific monoclonal antibodies reactive with the modified nucleoside structure 8-OH-Ade, and to various immunoassays for 8-OH-Ade utilizing these monoclonal antibodies. The monoclonal antibodies of the present invention may be used in assays for diagnosing or monitoring the progression of certain types of cancer, in addition to a variety of other diseases associated with mutagenesis resulting from oxidative damage of DNA. Assays utilizing the monoclonal antibodies of the present invention may also be used to analyze or monitor toxicant exposure, such as from environmental sources. The monoclonal antibodies of the present invention were prepared with the immunogen 8-OH-adenosine coupled to keyhole limpet hemocyanin (KLH), not to 8-OH-Ade directly.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: May 31, 2005
    Assignee: CytoChem, Inc.
    Inventors: Eric H. Holmes, Thomas G. Greene